178 related articles for article (PubMed ID: 35165100)
1. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
van Linde ME; Labots M; Brahm CG; Hovinga KE; De Witt Hamer PC; Honeywell RJ; de Goeij-de Haas R; Henneman AA; Knol JC; Peters GJ; Dekker H; Piersma SR; Pham TV; Vandertop WP; Jiménez CR; Verheul HMW
Clin Cancer Res; 2022 Apr; 28(8):1595-1602. PubMed ID: 35165100
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
Costa PM; Cardoso AL; Nóbrega C; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC
Hum Mol Genet; 2013 Mar; 22(5):904-18. PubMed ID: 23201752
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib activates Axl signaling in renal cell cancer.
van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
[TBL] [Abstract][Full Text] [Related]
6. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
[TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of sunitinib: A new therapeutic approach for targeting angiogenesis of glioblastoma.
Seidkhani E; Moradi F; Rustamzadeh A; Simorgh S; Shirvalilou S; Mehdizadeh M; Dehghani H; Akbarnejad Z; Motevalian M; Gorgich EAC
Toxicol Appl Pharmacol; 2023 Dec; 481():116754. PubMed ID: 37956929
[TBL] [Abstract][Full Text] [Related]
8. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
D'Amico R; Lei L; Kennedy BC; Sisti J; Ebiana V; Crisman C; Christensen JG; Gil O; Rosenfeld SS; Canoll P; Bruce JN
Neurol Res; 2012 Apr; 34(3):252-61. PubMed ID: 22449730
[TBL] [Abstract][Full Text] [Related]
9. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.
Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA
J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
[TBL] [Abstract][Full Text] [Related]
11. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
[TBL] [Abstract][Full Text] [Related]
12. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Dudek AZ; Raza A; Chi M; Singhal M; Oberoi R; Mittapalli RK; Agarwal S; Elmquist WF
Clin Genitourin Cancer; 2013 Jun; 11(2):155-60. PubMed ID: 23265925
[TBL] [Abstract][Full Text] [Related]
13. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
14. Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.
Grisanti S; Ferrari VD; Buglione M; Agazzi GM; Liserre R; Poliani L; Buttolo L; Gipponi S; Pedersini R; Consoli F; Panciani P; Roca E; Spena G; Triggiani L; Berruti A;
J Neurosurg Sci; 2019 Aug; 63(4):458-467. PubMed ID: 27680966
[TBL] [Abstract][Full Text] [Related]
15. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
16. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
17. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
Tripathi PH; Akhtar J; Arora J; Saran RK; Mishra N; Polisetty RV; Sirdeshmukh R; Gautam P
BMC Cancer; 2022 Feb; 22(1):133. PubMed ID: 35109816
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
Gotink KJ; Broxterman HJ; Labots M; de Haas RR; Dekker H; Honeywell RJ; Rudek MA; Beerepoot LV; Musters RJ; Jansen G; Griffioen AW; Assaraf YG; Pili R; Peters GJ; Verheul HM
Clin Cancer Res; 2011 Dec; 17(23):7337-46. PubMed ID: 21980135
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]